October 30, 2007 – Leake publishes White Paper on the potential advantages of using an independent, third-party for the storage of Bioequivalence/Bioavailability Retention Samples.
Often, the offices of investigator sites or CROs don’t provide the optimum environment for the storage of Retention Samples from Bioequivalence (BE) or Bioavailability (BA) studies. Storage space, temperature, security and experience are all considerations when planning for the retention of these critical samples. If you are faced with deficiencies in any of these areas, it might be beneficial to consider the alternative approved by the FDA: an independent, third-party contractor to store your samples. (Click here to find out more) |
|
